Wakefield, Mass., April 25th, 2023- Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.